TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Brief Motivational Intervention Including Counter-marketing Arguments With a Population of Patients With Moderate to Severe Alcohol Use Disorders Who Are Followed up on an Outpatient Basis (Primary Care or Addictology) (DEPREV_Phase 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~- Patient over 18 years of age~* Current alcohol consumption (several times a month)~* Compliance with the criteria for harmful use or dependence according to AUDIT scale greater than or equal to 7 for men or 6 for women~* Outpatient follow-up in primary care or in addictology in the addictology network of northern Finistère~Exclusion Criteria :~* Patient under 18 years of age~* Subject under legal protection, guardianship, or curatorship or deprived of liberty~* Non comprehension of the French language~* Acute unstable psychiatric disorders affecting judgment~* No fixed or cell phone line~* AUDIT score less than 6 for women and 7 for men~* Addictology hospitalization history in the last 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Motivational interview (Type: EXPERIMENTAL): Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient was randomized to the intervention group, the patient will receive 2 individual sessions (motivational interview) by telephone within 1 month of inclusion. They will then be assessed at month 1, month 3 and month 6. These assessments will be done by telephone.
- Routine Care (Type: ACTIVE_COMPARATOR): Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient has been randomized to the control group, the patient will be assessed at month 1, month 3 and month 6. These assessments will be done by telephone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients up to 18 years old with medullary thyroid cancer / carcinoma~* Patients with medullary thyroid cancer / carcinoma recurrence, which have a high calcitonin level / rate, more than 100pg/ml, associated - or not - to a high CEA (Carcinoembryonic Antibodies) level / rate, dated from less than 3 months~* Patients with a less than 3 months conventional imaging checkup (cervical ultrasonography, cervical-chest-abdomen tomography and / or magnetic resonance imaging, abdomen ultrasonography, osseous / bones radionuclide imaging), in which the tumor site not certainty located~* Informed Consent Form signed and dated by patients~* Patients which are SECURITE SOCIALE affiliated~Exclusion criteria:~* Pregnant or suckling women~* Women able to procreate, without efficient birth control~* Patients already included in another Nuclear Medicine or Imaging research protocol using ionizing radiations; the efficient dose accumulation will not exceed 20 mSv.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 18F-L6DOPA PET

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medical Use of Song In Critical Care (MUSIC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 yrs of age~* Admitted to Medical Intensive Care Unit (MICU) (3B and 3C) or Surgical Intensive Care Unit (SICU) (8C, 8D, 11C)~* Expected to receive mechanical ventilation ≥ 24hr~* Surrogate present to provide informed consent~Exclusion Criteria:~* Intubated at a transferring hospital for \> 24 hr before arrival to Brigham and Women's Hospital (BWH)~* Chronically ventilator dependent before admission to the hospital~* Transplant candidate or recipient~* Non-English speaking as the questionnaire has not been translated~* Prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Music (Type: EXPERIMENTAL): Everyone enrolled with receive music sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Yoga Therapy in Treating Patients With Malignant Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Signed protocol specific informed consent Are diagnosed with a Malignant Brain Tumor (Grades II-IV) Able to start the on-site yoga intervention within 1 week of first radiation treatment Are physically able to attend the intervention classes (Eastern Cooperative Oncology Group \[ECOG\] performance status rating 0-2) Able to understand written and spoken English Have no medical contraindications reported by the attending physician~Exclusion Criteria:~Have practiced yoga on a regular basis (at least once a week) within the past 4 weeks to recruit participants who are not already regularly practicing yoga; given that the benefits of yoga are likely more immediate than long-term, however, we will enroll participants who have previously had a yoga practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (yoga therapy) (Type: EXPERIMENTAL): Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of androgen-independent prostate cancer~  * Evidence of rising PSA level (with or without new lesion by radiograph or physical examination), defined as follows:~    * PSA level \> 5 ng/mL and clearly rising on 2 measurements taken ≥ 2 weeks apart after androgen deprivation therapy (i.e., orchiectomy or luteinizing hormone-releasing hormone \[LHRH\] analogue) and antiandrogen withdrawal, if appropriate~ * PSA rising before and on the first value taken at 4 or 6 weeks after antiandrogen cessation is considered disease progression~* Measurable or evaluable disease as defined by any of the following:~  * Measurable or evaluable tumor masses by radiograph or physical examination~ * Evaluable PSA~* Concurrent LHRH analogue or diethylstilbestrol (DES) for testicular androgen suppression required if no prior bilateral orchiectomy~  * Patients receiving other monotherapy for testicular androgen suppression must switch to a LHRH analogue or DES ≥ 14 days prior to study entry~PATIENT CHARACTERISTICS:~* ECOG 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Hemoglobin \> 8.9 g/dL (transfusion or erythropoietin support allowed)~* Serum creatinine ≤ 1.8 mg/dL~* AST ≤ 4 times upper limit of normal (ULN)~* Total bilirubin ≤ 2.0 mg/dL~* Serum corrected calcium \< ULN~* No history of nephrolithiasis within the past 5 years~* No unstable, uncontrolled peptic ulcer disease, congestive heart failure, glaucoma, HIV, or diabetes~PRIOR CONCURRENT THERAPY:~* At least 28 days since prior androgen deprivation therapy (≥ 42 days for bicalutamide)~  * A 28-day washout period is not required for patients who have previously progressed despite antiandrogen withdrawal and who have resumed antiandrogens without reduction of PSA~* At least 14 days since prior radiotherapy~* At least 28 days since prior strontium 89~* At least 28 days since prior chemotherapy and/or investigational agents~* No concurrent medications or supplements that contain additional calcium (e.g., Tums)~* No concurrent radiotherapy for pain control or any other indication~* Concurrent bisphosphonates allowed provided dose/regimen is stable

- Gender: MALE
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone and Calcitriol (Type: EXPERIMENTAL): Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* A diagnosis of allergic asthma, uncontrolled on current medication.~* History of at least 2 asthma exacerbations during the last 1 year~* Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted normal value; reversibility following administration of bronchodilator.~Key Exclusion Criteria:~* Use of tobacco products within the previous 6 months (Social occasional smokers may be included).~* Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 240 mg (Type: EXPERIMENTAL): QGE031 240 mg subcutaneous injection every 4 weeks
- QGE031 72 mg (Type: EXPERIMENTAL): QGE031 72 mg subcutaneous injection every 4 weeks
- QGE031 24 mg (Type: EXPERIMENTAL): QGE031 24 mg subcutaneous injection every 4 weeks
- Placebo to QGE031 (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* liver cirrhosis~* child pugh\>=B7~* studied for transplantation~* age between 18 an 65 ys~* no previous bleeding from varices~* signed informed consent~Exclusion Criteria:~* esophageal varices less than F2 blue~* gastric varices~* previous variceal surgical or radiological or endoscopical treatment~* hepatocarcinoma~* portal vein thrombosis~* severe heart, respiratory or renal failure~* contraindications to betablockers~* treatment with nitrates, calcium antagonist or anti-arhythmic drugs that can not be suspended~* Pregnancy~* neoplasias~* non cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients at least 18 years of age~* Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity of OAB (as defined by patient reported symptoms) for a minimum of one month prior to study entry~* Ability to use a toilet independently and without difficulty~* No treatment with any medication against OAB during the 4 weeks prior to study entry~* Written informed consent~Exclusion Criteria:~* Breastfeeding women, pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and not practicing a highly reliable method of birth control~* Any local pathology, that might cause the bladder symptoms~* Significant stress urinary incontinence or mixed stress/urgency incontinence~* Any neurological disease affecting bladder function or muscle strength~* Patient history of any lower urinary tract surgery or previous pelvic irradiation~* Local administration of botulinum toxin within the last 9 months in the lower urinary tract~* Start or change of a behavioral bladder training program~* Post voiding residual volumes larger than 250ml or symptoms of clinically relevant bladder outlet obstruction~* Nocturial polyuria~* History of liver disease and/or impaired liver function~* Cholestasis~* Chronic alcohol or drug abuse~* Evidence of significantly impaired renal function (~* Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or polyuria~* Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis~* Uncontrolled narrow angle glaucoma~* Chronic use of carbamazepine or paracetamol~* Participation in any drug study in the preceding 3 months~* Concomitant treatment with strong CYP3A4 inhibitors~* History or evidence of relevant cardiovascular or cerebrovascular disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Performance of General Practitioners in Compression UltraSound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Management by a general practitioner trained in 3-point venous ultrasound~* Suspicion of deep vein thrombosis by the general practitioner with prescription of a whole-leg Doppler ultrasound by a vascular physician. It is noted that the patient can be included from the moment the general practitioner had planned to refer the patient to the vascular physician for a suspicion of DVT, including in the absence of realization of DDimer on a low probability of DVT. It may also be included in case of positive DDimer tests.~* Signed written consent~* Patient covered by the French social security system~Exclusion Criteria:~* Whole leg ultrasound performed more than 72 hours after the initial examination~* History of homolateral deep vein thrombosis~* Patient objecting to the use of his data~* Refusal of written and signed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- compression ultrasound (Type: EXPERIMENTAL): All patients receive a 3-point compression ultrasound followed within 72 hours by a whole-leg ultrasound with Doppler performed by a vascular physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women eligible for gastric bypass surgery~* Pre-menopausal women~* All women will have signed an informed consent form prior to participating in study procedures~Exclusion Criteria:~* Women with a history of breast cancer~* Women currently taking exogenous hormone replacement therapy~* Women currently taking a SERM~* Women currently taking an aromatase inhibitor~* Pregnant or lactating women~* Women who have been pregnant or lactating in the past 2 years~* Women who have metallic or other surgical implants~* All subjects will have a determination of their estimated glomerular filtration rate (eGFR) within 24 hours of undergoing any study where gadolinium based contrast agents will be administered~* Subjects should not have a known history of recent onset acute renal dysfunction~* Subjects with a history of stable chronic renal dysfunction may participate in studies using GBCA based on their eGFR, as outlined below~* Subjects should not have severe liver dysfunction, particularly when associated with kidney disease~* Subjects should receive GBCAs in the perioperative period (i.e. within 4 weeks) after renal or liver transplantation

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): Participants who are eligible for and have opted to undergo gastric bypass surgery
- Group 2 (Type: None): Participants who are eligible for but decided not to undergo gastric bypass surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Human Placental Graft in Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* 18-80 years old~* Diagnosis of Type 1 or 2 Diabetes Mellitus~* Foot ulcers \>1cm2 and \<25cm2 for 4 weeks or more prior to enrollment~* Able to give consent to participate~* Compliance with all aspects of protocol and follow-up~Exclusion Criteria:~* Male and female patients younger than 18 years old~* Male or female patients older than 80 years old~* Smoking, and any additional health risk factors contraindicated with Revita use~* Involvement in any other ongoing studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Treatment (Type: EXPERIMENTAL): Will receive Revita allograft for wound treatment
- Control (Type: NO_INTERVENTION): Will receive current standard of care for wound treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan for Patients With Acute Neurological Injuries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with euvolemic or hypervolemic hyponatremia: serum Na \<135 meq/dl~* Inappropriately high urinary sodium excretion~Exclusion Criteria:~* Clinically evident hypovolemic hyponatremia~* Recent myocardial infarction or cardiac surgery~* Sustained ventricular tachycardia or fibrillation~* Systolic blood pressure of less than 90 mm Hg~* Serum creatinine concentration of more than 3 mg per deciliter~* History of, or biochemical evidence of, liver disease~* Serum sodium concentration less than 120 mmol per liter in association with neurologic impairment~* Urinary tract obstruction~* Use of other diuretics (furosemide, burinex, hydrochlorthiazide) that cannot be safely discontinued~* Concomitant use of hypertonic saline (prior use OK, if hypertonic is stopped within 1 hour of the first dose of Tolvaptan administration).~* History of chronic SIADH or known chronic hyponatremia from other causes (e.g. heart failure)~* Uncontrolled hypothyroidism or adrenal insufficiency~* Severe co-morbidities with life expectancy \<6 months~* CMO status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: OTHER): Intervention arm. Open label, no control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 30-80, both genders~* Parkinson's disease patients~* Parkinson's disease patients with G2019S mutations~* Controls: patient at risk of colic cancer for whom a coloscopy is required

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colonic biopsies (Type: OTHER): Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy